Drug intelligence / Profile preview

Shenqi Fuwei Mixture

Development stage: Unknown
Lead developer: Hunan Cancer Hospital
Administration: Oral

Overview

Shenqi Fuwei Mixture is a Traditional Chinese Medicine (TCM) formulation developed by Hunan Cancer Hospital. It is primarily investigated as an adjuvant therapy for locally advanced gastric cancer, specifically to be used in combination with neoadjuvant chemotherapy. The mixture is intended to reduce postoperative recurrence and metastasis. While the exact herbal composition is not detailed in the provided context, the name "Shenqi" typically implies the inclusion of *Ginseng* (Renshen) and *Astragalus* (Huangqi), which are often used in TCM to bolster the "Qi" and support the immune system. The clinical study aims to explore its efficacy, safety, and potential mechanisms through multi-omics and TCM syndrome analysis.

Other names: Shenqi Fuwei Heji参芪扶胃合剂

Targets

IL10 (Interleukin-10)

Beyond the preview

Go deeper on Shenqi Fuwei Mixture.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenqi Fuwei Mixture.

Explore the full profile